|
1
|
Gallagher JC and Levine JP: Preventing
osteoporosis in symptomatic postmenopausal women. Menopause.
18:109–118. 2011. View Article : Google Scholar
|
|
2
|
Sultan N and Rao J: Association between
periodontal disease and bone mineral density in postmenopausal
women: A cross sectional study. Med Oral Patol Oral Cir Bucal.
16:e440–e447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee BD and White SC: Age and trabecular
features of alveolar bone associated with osteoporosis. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 100:92–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Streckfus CF, Johnson RB, Nick T, Tsao A
and Tucci M: Comparison of alveolar bone loss, alveolar bone
density and second metacarpal bone density, salivary and gingival
crevicular fluid interleukin-6 concentrations in healthy
premenopausal and postmenopausal women on estrogen therapy. J
Gerontol A Biol Sci Med Sci. 52:M343–M351. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tezal M, Wactawski-Wende J, Grossi SG,
Dmochowski J and Genco RJ: Periodontal disease and the incidence of
tooth loss in postmenopausal women. J Periodontol. 76:1123–1128.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Civitelli R, Pilgram TK, Dotson M,
Muckerman J, Lewandowski N, Armamento-Villareal R,
Yokoyama-Crothers N, Kardaris EE, Hauser J, Cohen S, et al:
Alveolar and postcranial bone density in postmenopausal women
receiving hormone/estrogen replacement therapy: A randomized,
double-blind, placebo-controlled trial. Arch Intern Med.
162:1409–1415. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu J, Cao Z and Li C: Intermittent PTH
administration: A novel therapy method for periodontitis-associated
alveolar bone loss. Med Hypotheses. 72:294–296. 2009. View Article : Google Scholar
|
|
8
|
Palomo L, Bissada NF and Liu J:
Periodontal assessment of postmenopausal women receiving
risedronate. Menopause. 12:685–690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Strom BL, Schinnar R, Weber AL, Bunin G,
Berlin JA, Baumgarten M, DeMichele A, Rubin SC, Berlin M, Troxel
AB, et al: Case-control study of postmenopausal hormone replacement
therapy and endometrial cancer. Am J Epidemiol. 164:775–786. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rossing MA, Cushing-Haugen KL, Wicklund
KG, Doherty JA and Weiss NS: Menopausal hormone therapy and risk of
epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev.
16:2548–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rizzoli R, Reginster JY, Boonen S, Bréart
G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA and Cooper C:
Adverse reactions and drug-drug interactions in the management of
women with postmenopausal osteoporosis. Calcif Tissue Int.
89:91–104. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Woo SB, Hellstein JW and Kalmar JR:
Narrative [corrected] review: Bisphosphonates and osteonecrosis of
the jaws. Ann Intern Med. 144:753–761. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clemett D and Spencer CM: Raloxifene: A
review of its use in postmenopausal osteoporosis. Drugs.
60:379–411. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sugimoto H1, Watanabe K, Toyama T,
Takahashi SS, Sugiyama S, Lee MC and Hamada N: Inhibitory effects
of French pine bark extract, Pycnogenol®, on alveolar
bone resorption and on the osteoclast differentiation. Phytother
Res. 29:251–259. 2015. View
Article : Google Scholar
|
|
15
|
Sağlam M, Köseoğlu S, Hatipoğlu M, Esen HH
and Köksal E: Effect of sumac extract on serum oxidative status,
RANKL/OPG system and alveolar bone loss in experimental
periodontitis in rats. J Appl Oral Sci. 23:33–41. 2015. View Article : Google Scholar
|
|
16
|
Guimarães MV, Melo IM, Adriano Araújo VM,
Tenazoa Wong DV, Roriz Fonteles CS, Moreira Leal LK, Ribeiro RA and
Lima V: Dry extract of Matricaria recutita L. (Chamomile) prevents
ligature-induced alveolar bone resorption in rats via inhibition of
tumor necrosis factor-α and interleukin-1β. J Periodontol.
87:706–715. 2016. View Article : Google Scholar
|
|
17
|
Feng XF, Huang LQ, Ge XG, Yang LJ and Yang
JY: Textual research on origin and development of genuine medicinal
herbs of Shanyao. Zhongguo Zhong Yao Za Zhi. 33:859–862. 2008.In
Chinese. PubMed/NCBI
|
|
18
|
Zhang Z, Xiang L, Bai D, Wang W, Li Y, Pan
J, Liu H, Wang S, Xiao GG and Ju D: The protective effect of
Rhizoma Dioscoreae extract against alveolar bone loss in
ovariectomized rats via regulating Wnt and p38 MAPK signaling.
Nutrients. 6:5853–5870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blanchard F, Duplomb L, Baud' huin M and
Brounais B: The dual role of IL-6-type cytokines on bone remodeling
and bone tumors. Cytokine Growth Factor Rev. 20:19–28. 2009.
View Article : Google Scholar
|
|
20
|
Sims NA and Walsh NC: GP130 cytokines and
bone remodelling in health and disease. BMB Rep. 43:513–523. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Z, Song C, Zhang F, Xiang L, Chen Y,
Li Y, Pan J, Liu H, Xiao GG and Ju D: Rhizoma Dioscoreae extract
protects against alveolar bone loss in ovariectomized rats via
microRNAs regulation. Nutrients. 7:1333–1351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Z, Xiang L, Bai D, Fu X, Wang W, Li
Y, Liu H, Pan J, Li Y, Xiao GG, et al: Treatment with Rhizoma
Dioscoreae extract has protective effect on osteopenia in
ovariectomized rats. ScientificWorldJournal.
2014:6459752014.PubMed/NCBI
|
|
23
|
Hidaka S, Okamoto Y, Yamada Y, Kon Y and
Kimura T: A Japanese herbal medicine, Chujo-to, has a beneficial
effect on osteoporosis in rats. Phytother Res. 13:14–19. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang J, Pham SM and Crabbe DL:
High-resolution micro-CT evaluation of mid- to long-term effects of
estrogen deficiency on rat trabecular bone. Acad Radiol.
10:1153–1158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bouxsein ML, Boyd SK, Christiansen BA,
Guldberg RE, Jepsen KJ and Müller R: Guidelines for assessment of
bone microstructure in rodents using micro-computed tomography. J
Bone Miner Res. 25:1468–1486. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garbers C, Hermanns HM, Schaper F,
Müller-Newen G, Grötzinger J, Rose-John S and Scheller J:
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine
Growth Factor Rev. 23:85–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grant SL and Begley CG: The oncostatin M
signalling pathway: Reversing the neoplastic phenotype? Mol Med
Today. 5:406–412. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mosley B, De Imus C, Friend D, Boiani N,
Thoma B, Park LS and Cosman D: Dual oncostatin M (OSM) receptors.
Cloning and characterization of an alternative signaling subunit
conferring OSM-specific receptor activation. J Biol Chem.
271:32635–32643. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lindberg RA, Juan TS, Welcher AA, Sun Y,
Cupples R, Guthrie B and Fletcher FA: Cloning and characterization
of a specific receptor for mouse oncostatin M. Mol Cell Biol.
18:3357–3367. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bellido T, Borba VZ, Roberson P and
Manolagas SC: Activation of the Janus kinase/STAT (signal
transducer and activator of transcription) signal transduction
pathway by interleukin-6-type cytokines promotes osteoblast
differentiation. Endocrinology. 138:3666–3676. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Itoh S, Udagawa N, Takahashi N, Yoshitake
F, Narita H, Ebisu S and Ishihara K: A critical role for
interleukin-6 family-mediated Stat3 activation in osteoblast
differentiation and bone formation. Bone. 39:505–512. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bellido T, O' Brien CA, Roberson PK and
Manolagas SC: Transcriptional activation of the p21(WAF1, CIP1,
SDI1) gene by interleukin-6 type cytokines. A prerequisite for
their pro-differentiating and anti-apoptotic effects on human
osteoblastic cells. J Biol Chem. 273:21137–21144. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jilka RL, Weinstein RS, Bellido T, Parfitt
AM and Manolagas SC: Osteoblast programmed cell death (apoptosis):
modulation by growth factors and cytokines. J Bone Miner Res.
13:793–802. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Palmqvist P, Persson E, Conaway HH and
Lerner UH: IL-6, leukemia inhibitory factor, and oncostatin M
stimulate bone resorption and regulate the expression of receptor
activator of NF-kappa B ligand, osteoprotegerin, and receptor
activator of NF-kappa B in mouse calvariae. J Immunol.
169:3353–3362. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim S, Yamazaki M, Shevde NK and Pike JW:
Transcriptional control of receptor activator of nuclear
factor-kappaB ligand by the protein kinase A activator forskolin
and the transmembrane glycoprotein 130-activating cytokine,
oncostatin M, is exerted through multiple distal enhancers. Mol
Endocrinol. 21:197–214. 2007. View Article : Google Scholar
|
